ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date

Monday, November 14, 2016

9:00AM-11:00AM
Abstract Number: 1511
Impacts of Disease Activity and Serum Level of Neurotrophic Factors on Depression in Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications
9:00AM-11:00AM
Abstract Number: 1148
Implementation of a Gout Knowledge Based Assessment Tool in an Inter-Professional, Multi-Disciplinary Musculoskeletal Training Program
Education - Poster
9:00AM-11:00AM
Abstract Number: 1152
Implementation of a Musculoskeletal Ultrasound Teaching Program Is Not Determined By Fellowship Program Size
Education - Poster
9:00AM-11:00AM
Abstract Number: 1263
Implicit Biases Influencing Service Provision in Physical Therapy for Low Back Pain
Healthcare Disparities in Rheumatology - ARHP Poster
9:00AM-11:00AM
Abstract Number: 1376
In Juvenile Dermatomyositis, Organ Damage Is Comparable after Median 13.5 and 21.5 Years Follow-up Time, Despite Sustained Disease Activity
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome
9:00AM-11:00AM
Abstract Number: 1626
In Real Life Rheumatoid Arthritis Patients, Leflunomide Has Limited Impact As a Second Line DMARD after Methotrexate
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II
9:00AM-11:00AM
Abstract Number: 1205
In silico Drug Repurposing Analysis Supports Phosphoinositol 3 Kinase Inhibitors As Treatment of LUPUS
Genetics, Genomics and Proteomics - Poster II
9:00AM-11:00AM
Abstract Number: 1611
In Vitro Cellular Profiling of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Reveals a Distinct Phenotypic Signature Compared to Tocilizumab, an Anti–IL-6 Receptor Monoclonal Antibody
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II
9:00AM-11:00AM
Abstract Number: 1110
Inactive Rhomboid Family Member 2/Tnfα Convertase/Tnfα Pathway Is Essential to the Pathogenesis of Haemophilic Arthropathy
Biology and Pathology of Bone and Joint - Poster II
9:00AM-11:00AM
Abstract Number: 1190
Incidence and Prevalence of Polymyalgia Rheumatic and Giant Cell Arteritis: A 15-Year Study in a Health Care Management Organization
Epidemiology and Public Health - Poster II
9:00AM-11:00AM
Abstract Number: 1167
Incidence of Primary Chronic Cutaneous Lupus Erythematosus in a Metropolitan Area of the Southeastern United States: The Georgia Lupus Registry
Epidemiology and Public Health - Poster II
9:00AM-11:00AM
Abstract Number: 1312
Incidence of Reactive Arthritis, Uveitis and Conjunctivitis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy: A 20 Years’ Two-Center Retrospective Study
Infection-related Rheumatic Disease - Poster
9:00AM-11:00AM
Abstract Number: 1489
Incident Hypertension and Associated Factors in a Hispanic Group with Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications
9:00AM-11:00AM
Abstract Number: 1409
Increase in the Use of Validated Disease Activity Scores in Current Daily Clinical Practice Compared to 2007
Quality Measures and Quality of Care - Poster II
9:00AM-11:00AM
Abstract Number: 1569
Increased Circulating CD14brightCD16+ Intermediate Monocytes Are Regulated By Interleukin-10 in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II
  • «Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 68
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology